Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

10/22/2026, 1:00 PM • GlobeNewswire

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF

Vanguard Health Care ETF (VHT) and iShares U.S. Healthcare ETF (IYH) both provide U.S. healthcare sector exposure with identical 5-year returns, but VHT offers significantly better value with 411 holdings, a lower 0.09% expense ratio versus IYH's 0.37%, and a higher 1.4% dividend yield. While IYH takes a more concentrated approach with 100 stocks focused on large-cap healthcare companies, VHT is recommended for most investors seeking lower costs and broader diversification.

10/21/2026, 6:30 PM • The Motley Fool

Abbott: 3 Key Takeaways for Long-Term Investors

Abbott announced plans to spin off its nutrition business into an independent public company, focusing on higher-margin medical technologies and diagnostics. The company reported 7% year-over-year comparable sales growth in Q3 2026, with cancer diagnostics sales up 14% driven by Cologuard and new blood-based colorectal cancer screening tests. Pulsed field ablation technology is accelerating growth in electrophysiology, positioning Abbott for accelerated growth beyond historical rates.

10/21/2026, 4:15 PM • The Motley Fool

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR. North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

10/21/2026, 1:00 PM • GlobeNewswire

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026

Moderna has surged over 600% in 2026, driven by breakthrough Phase 3 trial results for its personalized cancer vaccine (intismeran autogene) combined with Merck's Keytruda, plus FDA approval for its flu vaccine mFLUSIVA. However, despite strong innovation, the stock appears overvalued at a $90 billion market cap with a 45% downside according to Wall Street analysts. The company would need to generate unrealistic revenue levels to justify current valuations, leaving little room for error.

10/21/2026, 10:00 AM • The Motley Fool

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

Johnson & Johnson and Amgen have outperformed the broader market in 2026 despite facing near-term challenges. JNJ's medtech division struggles with its Impella heart pump facing safety concerns and recalls, but its innovative medicines segment and new products like OTTAVA robotic surgery system offer long-term growth. Amgen faces regulatory pressure on Tavneos and patent losses on denosumab, but strong pipeline candidates like MariTide and established growth drivers like Tezspire and Tepezza support its outlook. Both companies maintain excellent dividend track records, making them solid long-term income investments.

10/20/2026, 4:40 PM • The Motley Fool

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors

Mestag Therapeutics announced the appointment of Philip Astley-Sparke and Victor Sandor, M.D.C.M. to its Board of Directors. Both appointees bring extensive biotech and oncology development experience. The appointments strengthen the Board as Mestag advances MST-0312, a targeted lymphotoxin-beta agonist bispecific antibody, in the Phase 1 STARLYS trial for patients with advanced solid tumors.

10/20/2026, 3:30 AM • GlobeNewswire

3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case.

Three Wall Street analysts have $500 price targets for Intuitive Surgical, citing strong growth in robot-assisted surgery procedures and the rollout of the da Vinci 5 platform. The company benefits from a recurring revenue model through instruments and accessories, with procedures growing 15% year-over-year. However, the stock's high P/E ratio of ~49 leaves limited room for disappointment.

10/19/2026, 9:30 AM • The Motley Fool

Should You Invest in This Dividend King on the Dip?

Johnson & Johnson reported strong Q3 results with revenue beating expectations and raised full-year guidance, driven by excellent pharmaceutical segment performance including cancer drug Darzalex and autoimmune treatment Tremfya. However, the medtech division underperformed, particularly due to safety concerns with Impella heart pumps. Despite near-term headwinds, the article argues J&J remains a solid long-term buy given its robust pharmaceutical pipeline, upcoming medtech innovations like robotic surgery devices, and its status as a Dividend King with 64 consecutive years of dividend increases.

10/17/2026, 10:52 AM • The Motley Fool

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

Johnson & Johnson raised its full-year sales and earnings guidance after beating Q3 estimates, but the stock fell 6% due to disappointing medical device sales. Despite near-term concerns about the MedTech division and a planned DePuy Synthes spinoff, the company's strong oncology business growth (16%+ in Q3) and reliable 64-year dividend streak make it an attractive long-term buy at current valuations.

10/17/2026, 6:15 AM • The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

10/16/2026, 8:50 PM • The Motley Fool

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.

10/16/2026, 1:54 PM • The Motley Fool

This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term

The Vanguard S&P 500 Growth ETF (VOOG) tracks the S&P 500 Growth index of 151 best-performing growth stocks, heavily weighted toward AI and technology companies. With a 16.9% compound annual return since 2010 and 28.4% over the last three years, consistent $500 monthly investments could potentially reach $1 million in approximately 23 years, even at conservative 14.1% annual returns.

10/16/2026, 9:04 AM • The Motley Fool

Breakfast News: Week in Review

Tech stocks faced headwinds this week as inflation concerns and rising bond yields pressured AI-related companies like Nvidia and Broadcom. CoreWeave's debt spike to $52 billion with 15% bond yields reignited AI debt bubble fears. Despite strong earnings, TSMC, Johnson & Johnson, and Morgan Stanley all sold off, while JPMorgan rallied on solid lending metrics. Consumer spending signals remain mixed, with JPMorgan seeing strength but Domino's warning of economic headwinds. Rocket Lab delayed Neutron's first flight to 2027 due to manufacturing issues. Valuation concerns persist across tech, with ASML, Atlassian, and Klarna highlighting the importance of entry price.

10/16/2026, 7:30 AM • The Motley Fool

Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading

Major stock indexes traded mixed on October 13, 2026, as bank earnings kicked off the season with varied results and semiconductor stocks faced significant selling pressure. The S&P 500 fell 0.25%, the Nasdaq dropped 0.37%, and the Dow declined 0.18%. Goldman Sachs gained on strong earnings, while Wells Fargo and Johnson & Johnson declined on disappointing results. Semiconductor stocks, particularly Micron Technology, slid over 5% amid intensifying global competition and Chinese chip innovations.

10/13/2026, 12:14 PM • The Motley Fool